Positive Results for NXP001 Clinical Trial

Cambridge, UK - 30th May 2019

Cambridge, UK, 29 May 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce positive results in its clinical study for the Company’s lead programme NXP001.

Download Document

Back to all Documents